Copyright
©The Author(s) 2020.
World J Gastroenterol. Oct 21, 2020; 26(39): 5919-5943
Published online Oct 21, 2020. doi: 10.3748/wjg.v26.i39.5919
Published online Oct 21, 2020. doi: 10.3748/wjg.v26.i39.5919
Table 1 Diagnostic performance of blood tests and scores for fibrosis assessment methods from studies made in patients with non-alcoholic fatty liver disease
Population (n) | Ref. | Cutoffs | Se | Sp | PPV | NPV | AUROC | |
FIB-4 (age, platelet count, AST and ALT) | 541 | [52] | ≤ 1.3 NF | 74% | 71% | 43% | 90% | 0.802 |
≥ 2.67 AF | 33% | 98% | 80% | 83% | ||||
153 | [53] | ≥ 1.3 AF | 87% | 60% | NA | NA | 0.895 | |
452 | [56] | ≥ 1.5 AF | 75% | 67% | 58% | 82% | 0.780 | |
328 | [57] | ≤ 1.3 NF | 56% | 56% | 22% | 85% | 0.540 | |
≥ 2.67 AF | 22% | 87% | 27% | 84% | ||||
APRI (AST and platelet count) | 153 | [53] | > 1 AF | 78% | 82% | NA | NA | 0.830 |
> 2 AF | 28% | 92% | NA | NA | ||||
452 | [56] | > 0.559 AF | 62% | 76% | 61% | 76% | 0.754 | |
NFS (age, glycaemia, BMI, platelet count, albumin, AST and ALT) | 480 | [55] | ≤ -1.455 NAF | 82% | 77% | 56% | 93% | 0.820 |
≥ 0.676 AF | 51% | 98% | 90% | 85% | ||||
126 | [58] | ≤ -1.455 NAF; ≥ 0.676 AF | 96% | 84% | 70% | 98% | 0.919 | |
138 | [59] | ≤ -1.455 NAF | 22% | 100% | 100% | 81% | 0.680 | |
≥ 0.676 AF | ||||||||
452 | [56] | > -1.036 AF | 77% | 60% | 54% | 81% | 0.732 | |
328 | [57] | ≤ -1.455 NAF | 53% | 67% | 26% | 87% | 0.640 | |
122 | [61] | ≥ 0.676 AF | 9% | 98% | 50% | 83% | 0.840 | |
NA | NA | 59% | 89% | |||||
BARD (BMI > 28 kg/m2, AST/ALT ratio > 0.8 and diabetes) | 126 | [58] | 0-1 NAF | 89% | 89% | 69% | 97% | 0.919 |
2-4 AF | ||||||||
138 | [59] | 0-1 NAF | 51% | 77% | 45% | 81% | 0.670 | |
2-4 AF | ||||||||
160 | [60] | 0-1 NAF | NA | NA | 27% | 97% | 0.780 | |
2-4 AF | ||||||||
452 | [56] | 2-4 AF | 79% | 51% | 50% | 80% | 0.695 | |
122 | [61] | 2-4 AF | NA | NA | 59% | 77% | 0.730 | |
328 | [57] | 2-4 AF | 83% | 37% | 22% | 91% | 0.594 | |
Fibrometer NAFLD | 452 | [56] | ≥ 0.311 AF | 80% | 62% | 56% | 83% | 0.817 |
Hepascore (age, sex, bilirubin, GGT, hyaluronic acid, and a2-macroglobulin) | 452 | [56] | ≥ 0.322 AF | 67% | 76% | 63% | 79% | 0.778 |
Fibrotest (α-2-macroglobulin, haptoglobin, apolipoprotein A1, GGT, and TB) | 452 | [56] | ≥ 0.316 AF | 81% | 57% | 54% | 83% | 0.736 |
HFS (sex, age, HOMA score, diabetes, AST, albumin, and platelets) | 2452 | [69] | < 0.12 NAF | 73.9% | 77.4% | 46% | 91.9% | 0.848 |
≥ 0.47 AF | 35.2% | 97.2% | 76.3% | 85.2% | ||||
49 | [70] | ≥ 0.47 AF | 11% | 100% | 100% | 83% | NA |
- Citation: Campos-Murguía A, Ruiz-Margáin A, González-Regueiro JA, Macías-Rodríguez RU. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2020; 26(39): 5919-5943
- URL: https://www.wjgnet.com/1007-9327/full/v26/i39/5919.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i39.5919